secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2024-10-02T23:59:59+00:00
Accession:  0001140361-24-042537
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech: 84.4% 36-month OS in cervical cancer trial of Versamune HPV + chemoradiation
--------------------------------------------------------------------------------

- 36-month OS rate 84.4% (all patients) vs ~64% historical; 100% in 8 patients receiving all 5 doses.
- 36-month PFS rate 74.9% overall, 100% in fully dosed subgroup; historical ~61%.
- Complete metabolic response (CMR) in 88% (15/17) of patients at 4 months per PET.
- Versamune HPV well-tolerated; most common related AE injection site reaction (71%).
- Median follow-up 19 months; data presented at ASTRO 2024, awarded Basic/Translational Science Award.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124042537/0001140361-24-042537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124042537/ef20036539_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-042537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer